Press release: STADA sustains strong momentum with double-digit sales and profit growth in 2022
Ein Dokument
mehr
Storys zum Thema Pharmaindustrie
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
mehrSuccessful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan
Munich / Paris / Tokyo (ots) - - Adragos Pharma now third largest pure-play CDMO in the Japanese market - Long-term agreement with Sanofi secures local healthcare supply Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading ...
mehrJanneke van der Kamp starts as new Chief Commercial Officer at Grünenthal
mehrInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
Ein DokumentmehrPress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
Ein DokumentmehrGerresheimer and Corning announce joint venture to meet growing demand for Velocity® Vials, accelerating the delivery of lifesaving treatments
Düsseldorf (ots) - Gerresheimer AG, the leading global provider of healthcare, beauty, and drug delivery systems for pharma, biotech, and cosmetics, today announced a joint venture with Corning Incorporated (NYSE: GLW), a leading innovator in materials science and manufacturing, to increase global access to the ...
mehrDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
mehrPress release: STADA appoints Boris Döbler as Chief Financial Officer
Ein DokumentmehrHearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
mehrPress release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
Ein DokumentmehrGerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
Düsseldorf (ots) - At today’s Capital Markets Day, Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirmed its growth agenda and increased its revenue and adjusted ...
Ein DokumentmehrTechnische Universität München
Nanoswitches for tumor targeting
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...
mehrStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research
mehrAdragos Pharma to acquire Sanofi's manufacturing site in Kawagoe, Japan
mehrbenfovir AG has reached another milestone by completing the first part of the Phase 1 trial testing transketolase inhibitor / benfo-oxythiamine (B-OT)
Darmstadt (ots) - benfovir AG, a German pharmaceutical company focused on developing small molecules against viral infections such as SARS-CoV-2, dengue and herpes virus, today announced that the first part of the Phase 1 clinical trial (BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, ...
mehrLeukocare announces new management structure to support global set-up and accelerate growth
Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the introduction of a new management structure, effective July 1st, 2022, designed to support the global organizational set-up and to further accelerate the company’s growth. The newly established Executive Board ...
mehrbenfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT/ B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS
Darmstadt (ots) - benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers. benfovir AG, a German pharmaceutical biotechnology company focused on developing small molecules against viral infection such as ...
mehrTechnische Universität München
Multi-functional bandage helps wounds to heal
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808- email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37410 Pictures: https://mediatum.ub.tum.de/1659268 NEWS RELEASE Biomolecular film adheres to sensitive tissue and releases active ingredients Multi-functional bandage helps wounds to heal Researchers at the ...
mehrHPDC Launches the World’s First All-in-One Supply Chain Management Solution for Advanced & Personalized Therapies
Munich/Nice (ots) - Hypertrust Patient Data Care (HPDC) today announced the global launch of its extended Hypertrust X-Chain supply chain management solution for Advanced & Personalized Therapies (APT). It is the worldwide first solution that allows biotech and pharmaceutical companies to design, set up, plan, ...
mehrQ-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass
BOSTON, MA (ots) - --News Direct-- Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed an agreement with In vitro Plant-tech AB, a Swedish plant cell cultivation company whose ...
mehrUniversity of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...
mehrTechnische Universität München
mRNA containing nanoparticles in the light of neutrons - investigations at FRM II aid in the development of mRNA medications
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37120 High resolution images: https://mediatum.ub.tum.de/1638436 NEWS RELEASE Optimization of mRNA ...
mehrBrenntag’s Pharma section signs exclusive agreement for health-promoting product line Akovita ELIP in EMEA
Ein DokumentmehrNew therapeutic approach against SARS-CoV-2 successfully tested
Pfungstadt (ots) - - Scientists at the Universities of Frankfurt a.M. and Kent (UK) have identified a metabolic pathway (pentose-phosphate pathway) that is crucial for the propagation of the SARS-CoV-2 virus in human cells. - The compound benfo-oxythiamine, an inhibitor of this metabolic pathway, has succeeded in blocking the replication of the SARS-CoV-2 virus in human cells. - Preclinical testing of this compound has ...
mehrCosmetics: Glucosides ensure increased bioavailability
C osmetics: Glucosides ensure increased bioavailability Glucosides eliminate the need for microplastics and provide increased bioavailability in cosmetic applications Freising/Germany, December 9, 2021 – Conventional active ingredients and fragrances in cosmetic products often evaporate shortly after application to the skin. Freising-based biotech company 4GENE has solved this problem by developing a special process ...
mehrAlmirall delivers solid nine months 2021 results and tightens its upgraded guidance
Barcelona, Spain (ots/PRNewswire) - - Strong Core business performance with growth in Core Net Sales EUR601.7 MM (+6.2% year-on-year) and Core EBITDA reaching EUR164.2 MM, (+20.3% year-on-year) driven by positive contribution from Growth Drivers and a strong EU dermatology performance - Key Growth Drivers underpinning increase in Core Net Sales. Strong performance from ...
mehr- 2
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
Ein Dokumentmehr Dr. Dirk Winnemöller joins Leukocare as Vice President Commercial
Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced that Dr. Dirk Winnemöller took up the newly established role as Vice President Commercial at Leukocare. Dirk joins the Company from Miltenyi Biomedicine GmbH, Bergisch Gladbach, Germany, where he served as Global Vice ...
mehrEleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production ...
mehr
Vorherige123456Nächste